TechBio and AI Centric Recursion (RXRX) Receives IND Application for REC-1245 to Treat Solid Tumors and Lymphoma
The PRISM NextGen Tech and AI Index and TechBio company Recursion (RXRX) is utilizing AI to decode biology and industrialize drug discovery. Today the company has announced the FDA has granted Recursion an Investigational New Drug (IND) application for a Phase 1/2 trial for REC-1245, which is a new chemical entity for the treatment of biomarker-enriched solid tumors and lymphoma.
Chris Gibson, Ph.D., Co-founder and CEO of Recursion said, “REC-1245 is a prime example of using an expansive AI-enabled platform for drug discovery. After exploring many predicted biological and chemical relationships across our maps of biology, we identified RMB39 as a novel target that looks functionally similar to the well-known but hard to drug target CDK12. We also identified and optimized small molecules that target RBM39 without directly impacting CDK12 or CDK13 using these same AI-enabled maps. In under 18 months, leveraging some of our newer chemistry tools, Recursion rapidly progressed REC-1245 from novel target biology to preclinical drug candidate, more than twice the speed of industry average.”
It is estimated that the initial addressable population for this potential therapeutic is >100,000 patients in the US and EU5. REC-1245 is a potent and selective RBM39 degrader with preclinical data that supports that RBM39 degradation prompts splicing defects that can then downregulate DNA Damage Response (DDR) networks and cell cycle checkpoints.
The Phase 1/2 clinical trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and potential monotherapy efficacy of REC-1245, and is expected to initiate in Q4 2024.
